HEADER HYDROLASE/HYDROLASE INHIBITOR 31-MAR-03 1OEX TITLE ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A TITLE 2 HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261 COMPND MOL_ID: 1; COMPND 2 MOLECULE: ENDOTHIAPEPSIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: RESIDUES 90-419; COMPND 5 SYNONYM: ASPARTATE PROTEASE, EAPA, EPN-1; COMPND 6 EC: 3.4.23.22; COMPND 7 OTHER_DETAILS: HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR COMPND 8 H261 BOUND AT ACTIVE SITE; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: INHIBITOR H261; COMPND 11 CHAIN: B; COMPND 12 ENGINEERED: YES; COMPND 13 OTHER_DETAILS: BOC-HIS-PRO-PHE-ALA-LOV-ILE-HIS SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: CRYPHONECTRIA PARASITICA; SOURCE 3 ORGANISM_COMMON: CHESTNUT BLIGHT FUNGUS; SOURCE 4 ORGANISM_TAXID: 5116; SOURCE 5 MOL_ID: 2; SOURCE 6 SYNTHETIC: YES; SOURCE 7 ORGANISM_SCIENTIFIC: SYNTHETIC CONSTRUCT; SOURCE 8 ORGANISM_TAXID: 32630 KEYWDS ASPARTIC PROTEINASE MECHANISM, ATOMIC RESOLUTION, SUCCINIMIDE, KEYWDS 2 ANISOTROPIC REFINEMENT, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR L.COATES,P.T.ERSKINE,S.MALL,R.S.GILL,S.P.WOOD,D.A.A.MYLES,J.B.COOPER REVDAT 8 15-NOV-23 1OEX 1 REMARK LINK ATOM REVDAT 7 24-JUL-19 1OEX 1 REMARK LINK REVDAT 6 08-FEB-17 1OEX 1 SOURCE REVDAT 5 13-JUL-11 1OEX 1 VERSN REVDAT 4 16-JUN-09 1OEX 1 REMARK REVDAT 3 24-FEB-09 1OEX 1 VERSN REVDAT 2 31-JUL-03 1OEX 1 JRNL REVDAT 1 02-APR-03 1OEX 0 JRNL AUTH P.T.ERSKINE,L.COATES,S.MALL,R.S.GILL,S.P.WOOD,D.A.A.MYLES, JRNL AUTH 2 J.B.COOPER JRNL TITL ATOMIC RESOLUTION ANALYSIS OF THE CATALYTIC SITE OF AN JRNL TITL 2 ASPARTIC PROTEINASE AND AN UNEXPECTED MODE OF BINDING BY JRNL TITL 3 SHORT PEPTIDES JRNL REF PROTEIN SCI. V. 12 1741 2003 JRNL REFN ISSN 0961-8368 JRNL PMID 12876323 JRNL DOI 10.1110/PS.0305203 REMARK 2 REMARK 2 RESOLUTION. 1.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 100.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.140 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.178 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 5285 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 105807 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : NULL REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.135 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.172 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 4.600 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 4821 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 96491 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2462 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 26 REMARK 3 SOLVENT ATOMS : 499 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : NULL REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : NULL REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 25 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 27154 REMARK 3 NUMBER OF RESTRAINTS : 33073 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.013 REMARK 3 ANGLE DISTANCES (A) : 0.028 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.032 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.079 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.078 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.074 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.005 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.030 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.071 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: MOEWS AND KRETSINGER REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1OEX COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 31-MAR-03. REMARK 100 THE DEPOSITION ID IS D_1290012473. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-JUN-98 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 4.60 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : EMBL/DESY, HAMBURG REMARK 200 BEAMLINE : BW7B REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.8340 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : AGROVATA, ROTAVATA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 105807 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.100 REMARK 200 RESOLUTION RANGE LOW (A) : 15.600 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 3.700 REMARK 200 R MERGE (I) : 0.12500 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 9.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.10 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.14 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.5 REMARK 200 DATA REDUNDANCY IN SHELL : 3.50 REMARK 200 R MERGE FOR SHELL (I) : 0.32000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 4.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: SHELXL-97 REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 38.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.99 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: BATCH METHOD WITH ENZYME AT A REMARK 280 CONCENTRATION OF 2 MG/ML IN 100 MM SODIUM ACETATE BUFFER AT PH REMARK 280 4.6 (MOEWS AND BUNN, 1970). CRYSTALS LEFT TO GROW FOLLOWING SLOW REMARK 280 ADDITION OF AMMONIUM SULPHATE TO FINAL CONCENTRATION OF 0.35 G/ REMARK 280 ML (55% SATURATION)., PH 4.60 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 37.25500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2610 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 12920 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -51.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 REMARK 400 THE H261 INHIBITOR IS PEPTIDE-LIKE, A MEMBER OF INHIBITOR CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: H261 INHIBITOR REMARK 400 CHAIN: B REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 SER A 82 CB SER A 82 OG -0.084 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 SUI A 54 CA - C - N ANGL. DEV. = -45.9 DEGREES REMARK 500 TYR A 58 CB - CG - CD2 ANGL. DEV. = 3.9 DEGREES REMARK 500 ASP A 118 CB - CG - OD1 ANGL. DEV. = 8.0 DEGREES REMARK 500 ASP A 118 CB - CG - OD2 ANGL. DEV. = -9.4 DEGREES REMARK 500 THR A 229 CA - CB - CG2 ANGL. DEV. = -8.8 DEGREES REMARK 500 PHE A 279 CB - CG - CD1 ANGL. DEV. = -4.7 DEGREES REMARK 500 SER A 288 C - N - CA ANGL. DEV. = 17.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 39 23.68 -140.66 REMARK 500 ALA A 128 -169.93 -77.58 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 LOV B 405 ILE B 406 -111.80 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 LOV B 405 35.89 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2021 DISTANCE = 6.03 ANGSTROMS REMARK 525 HOH A2045 DISTANCE = 5.83 ANGSTROMS REMARK 525 HOH A2049 DISTANCE = 7.02 ANGSTROMS REMARK 525 HOH A2075 DISTANCE = 6.84 ANGSTROMS REMARK 525 HOH A2113 DISTANCE = 5.91 ANGSTROMS REMARK 525 HOH A2204 DISTANCE = 6.37 ANGSTROMS REMARK 525 HOH B2001 DISTANCE = 5.85 ANGSTROMS REMARK 700 REMARK 700 SHEET REMARK 700 THE SHEET STRUCTURE OF THIS MOLECULE IS BIFURCATED. IN REMARK 700 ORDER TO REPRESENT THIS FEATURE IN THE SHEET RECORDS BELOW, REMARK 700 TWO SHEETS ARE DEFINED. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 410 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 500 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 503 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN B OF INHIBITOR H261 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1E5O RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH INHIBITOR DB2 REMARK 900 RELATED ID: 1E80 RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA- EMD56133 REMARK 900 RELATED ID: 1E81 RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA- EMD61395 REMARK 900 RELATED ID: 1E82 RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA- EMD59601 REMARK 900 RELATED ID: 1EED RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH THE CYCLOHEXYL RENIN INHIBITOR PD125754 REMARK 900 RELATED ID: 1ENT RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH THE INHIBITOR PD130328 REMARK 900 RELATED ID: 1EPL RELATED DB: PDB REMARK 900 RELATED ID: 1EPM RELATED DB: PDB REMARK 900 RELATED ID: 1EPN RELATED DB: PDB REMARK 900 RELATED ID: 1EPO RELATED DB: PDB REMARK 900 RELATED ID: 1EPP RELATED DB: PDB REMARK 900 RELATED ID: 1EPQ RELATED DB: PDB REMARK 900 RELATED ID: 1EPR RELATED DB: PDB REMARK 900 RELATED ID: 1ER8 RELATED DB: PDB REMARK 900 RELATED ID: 1GKT RELATED DB: PDB REMARK 900 NEUTRON LAUE DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH REMARK 900 TRANSITION STATE ANALOGUE INHIBITOR H261 REMARK 900 RELATED ID: 1GVT RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH CP-80,794 REMARK 900 RELATED ID: 1GVU RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH H189 REMARK 900 RELATED ID: 1GVV RELATED DB: PDB REMARK 900 FIVE ATOMIC RESOLUTION STRUCTURES OF ENDOTHIAPEPSIN INHIBITOR REMARK 900 COMPLEXES; IMPLICATIONS FOR THE ASPARTIC PROTEINASE MECHANISM REMARK 900 RELATED ID: 1GVW RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH PD-130,328 REMARK 900 RELATED ID: 1GVX RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEXED WITH H256 REMARK 900 RELATED ID: 1OD1 RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN PD135,040 COMPLEX REMARK 900 RELATED ID: 1OEW RELATED DB: PDB REMARK 900 ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN REMARK 900 RELATED ID: 2ER0 RELATED DB: PDB REMARK 900 RELATED ID: 2ER6 RELATED DB: PDB REMARK 900 RELATED ID: 2ER7 RELATED DB: PDB REMARK 900 RELATED ID: 2ER9 RELATED DB: PDB REMARK 900 RELATED ID: 3ER3 RELATED DB: PDB REMARK 900 RELATED ID: 3ER5 RELATED DB: PDB REMARK 900 RELATED ID: 4APE RELATED DB: PDB REMARK 900 RELATED ID: 4ER1 RELATED DB: PDB REMARK 900 RELATED ID: 4ER2 RELATED DB: PDB REMARK 900 RELATED ID: 4ER4 RELATED DB: PDB REMARK 900 RELATED ID: 5ER1 RELATED DB: PDB REMARK 900 RELATED ID: 5ER2 RELATED DB: PDB REMARK 999 REMARK 999 SEQUENCE REMARK 999 ASP A54 AND GLY A55 HAVE CYCLISED TO FORM A SUCCINIMIDE DBREF 1OEX A 1 329 UNP P11838 CARP_CRYPA 90 419 DBREF 1OEX B 400 407 PDB 1OEX 1OEX 400 407 SEQRES 1 A 329 SER THR GLY SER ALA THR THR THR PRO ILE ASP SER LEU SEQRES 2 A 329 ASP ASP ALA TYR ILE THR PRO VAL GLN ILE GLY THR PRO SEQRES 3 A 329 ALA GLN THR LEU ASN LEU ASP PHE ASP THR GLY SER SER SEQRES 4 A 329 ASP LEU TRP VAL PHE SER SER GLU THR THR ALA SER GLU SEQRES 5 A 329 VAL SUI GLN THR ILE TYR THR PRO SER LYS SER THR THR SEQRES 6 A 329 ALA LYS LEU LEU SER GLY ALA THR TRP SER ILE SER TYR SEQRES 7 A 329 GLY ASP GLY SER SER SER SER GLY ASP VAL TYR THR ASP SEQRES 8 A 329 THR VAL SER VAL GLY GLY LEU THR VAL THR GLY GLN ALA SEQRES 9 A 329 VAL GLU SER ALA LYS LYS VAL SER SER SER PHE THR GLU SEQRES 10 A 329 ASP SER THR ILE ASP GLY LEU LEU GLY LEU ALA PHE SER SEQRES 11 A 329 THR LEU ASN THR VAL SER PRO THR GLN GLN LYS THR PHE SEQRES 12 A 329 PHE ASP ASN ALA LYS ALA SER LEU ASP SER PRO VAL PHE SEQRES 13 A 329 THR ALA ASP LEU GLY TYR HIS ALA PRO GLY THR TYR ASN SEQRES 14 A 329 PHE GLY PHE ILE ASP THR THR ALA TYR THR GLY SER ILE SEQRES 15 A 329 THR TYR THR ALA VAL SER THR LYS GLN GLY PHE TRP GLU SEQRES 16 A 329 TRP THR SER THR GLY TYR ALA VAL GLY SER GLY THR PHE SEQRES 17 A 329 LYS SER THR SER ILE ASP GLY ILE ALA ASP THR GLY THR SEQRES 18 A 329 THR LEU LEU TYR LEU PRO ALA THR VAL VAL SER ALA TYR SEQRES 19 A 329 TRP ALA GLN VAL SER GLY ALA LYS SER SER SER SER VAL SEQRES 20 A 329 GLY GLY TYR VAL PHE PRO CYS SER ALA THR LEU PRO SER SEQRES 21 A 329 PHE THR PHE GLY VAL GLY SER ALA ARG ILE VAL ILE PRO SEQRES 22 A 329 GLY ASP TYR ILE ASP PHE GLY PRO ILE SER THR GLY SER SEQRES 23 A 329 SER SER CYS PHE GLY GLY ILE GLN SER SER ALA GLY ILE SEQRES 24 A 329 GLY ILE ASN ILE PHE GLY ASP VAL ALA LEU LYS ALA ALA SEQRES 25 A 329 PHE VAL VAL PHE ASN GLY ALA THR THR PRO THR LEU GLY SEQRES 26 A 329 PHE ALA SER LYS SEQRES 1 B 8 BOC HIS PRO PHE ALA LOV ILE HIS MODRES 1OEX SUI A 54 ASP MODRES 1OEX SUI A 54 GLY HET SUI A 54 11 HET BOC B 400 7 HET LOV B 405 15 HET GOL A 410 6 HET SO4 A 500 5 HET SO4 A 501 5 HET SO4 A 502 5 HET SO4 A 503 5 HETNAM SUI (3-AMINO-2,5-DIOXO-1-PYRROLIDINYL)ACETIC ACID HETNAM BOC TERT-BUTYL HYDROGEN CARBONATE HETNAM LOV 5-AMINO-4-HYDROXY-2-ISOPROPYL-7-METHYL-OCTANOIC ACID HETNAM GOL GLYCEROL HETNAM SO4 SULFATE ION HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 1 SUI C6 H8 N2 O4 FORMUL 2 BOC C5 H10 O3 FORMUL 2 LOV C12 H25 N O3 FORMUL 3 GOL C3 H8 O3 FORMUL 4 SO4 4(O4 S 2-) FORMUL 8 HOH *499(H2 O) HELIX 1 1 THR A 49 VAL A 53 5 5 HELIX 2 2 THR A 59 SER A 63 5 5 HELIX 3 3 SER A 112 ASP A 118 1 7 HELIX 4 4 PHE A 129 ASN A 133 5 5 HELIX 5 5 THR A 142 LYS A 148 1 7 HELIX 6 6 PRO A 227 ALA A 236 1 10 HELIX 7 7 PRO A 273 ILE A 277 1 5 HELIX 8 8 GLY A 305 LYS A 310 1 6 SHEET 1 AA 3 LYS A 67 SER A 77 0 SHEET 2 AA 3 SER A 83 VAL A 95 -1 O SER A 84 N ILE A 76 SHEET 3 AA 3 TYR A 17 ILE A 23 -1 O GLN A 22 N SER A 94 SHEET 1 AB 7 LYS A 67 SER A 77 0 SHEET 2 AB 7 SER A 83 VAL A 95 -1 O SER A 84 N ILE A 76 SHEET 3 AB 7 LEU A 98 VAL A 111 -1 O LEU A 98 N VAL A 95 SHEET 4 AB 7 LEU A 41 VAL A 43 1 O LEU A 41 N GLU A 106 SHEET 5 AB 7 GLY A 123 GLY A 126 -1 O LEU A 124 N TRP A 42 SHEET 6 AB 7 GLN A 28 ASP A 35 1 O ASP A 33 N LEU A 125 SHEET 7 AB 7 TYR A 17 ILE A 23 -1 O THR A 19 N LEU A 32 SHEET 1 AC 7 ALA A 268 ILE A 272 0 SHEET 2 AC 7 PHE A 261 VAL A 265 -1 O PHE A 261 N ILE A 272 SHEET 3 AC 7 GLU A 195 VAL A 203 -1 N THR A 199 O GLY A 264 SHEET 4 AC 7 LYS A 209 ALA A 217 -1 O LYS A 209 N TYR A 201 SHEET 5 AC 7 ASN A 302 PHE A 304 1 O ASN A 302 N ILE A 216 SHEET 6 AC 7 LEU A 224 LEU A 226 -1 O TYR A 225 N ILE A 303 SHEET 7 AC 7 ILE A 293 SER A 295 1 O GLN A 294 N LEU A 226 SHEET 1 AD 4 LYS A 242 SER A 244 0 SHEET 2 AD 4 GLY A 249 PRO A 253 -1 O GLY A 249 N SER A 244 SHEET 3 AD 4 SER A 288 GLY A 291 -1 O CYS A 289 N PHE A 252 SHEET 4 AD 4 ASP A 278 PRO A 281 -1 O GLY A 280 N PHE A 290 SSBOND 1 CYS A 254 CYS A 289 1555 1555 2.05 LINK C VAL A 53 N SUI A 54 1555 1555 1.32 LINK C SUI A 54 N GLN A 55 1555 1555 1.33 LINK C BOC B 400 N HIS B 401 1555 1555 1.34 LINK C ALA B 404 N LOV B 405 1555 1555 1.32 LINK C LOV B 405 N ILE B 406 1555 1555 1.33 CISPEP 1 THR A 25 PRO A 26 0 -7.53 CISPEP 2 SER A 136 PRO A 137 0 6.26 SITE 1 AC1 5 CYS A 254 ASP A 278 GLY A 280 PRO A 281 SITE 2 AC1 5 CYS A 289 SITE 1 AC2 7 TYR A 178 SER A 181 ILE A 182 HOH A2329 SITE 2 AC2 7 HOH A2473 HOH A2474 HOH A2475 SITE 1 AC3 10 SER A 112 SER A 113 THR A 321 HOH A2180 SITE 2 AC3 10 HOH A2221 HOH A2476 HOH A2477 HOH A2478 SITE 3 AC3 10 HOH A2479 HOH A2480 SITE 1 AC4 5 SER A 136 PRO A 137 HOH A2481 HOH A2483 SITE 2 AC4 5 HOH A2484 SITE 1 AC5 8 ALA A 268 ARG A 269 SER A 283 HOH A2331 SITE 2 AC5 8 HOH A2416 HOH A2437 HOH A2467 HOH A2485 SITE 1 AC6 35 LEU A 13 ASP A 15 ASP A 33 ASP A 35 SITE 2 AC6 35 GLY A 37 SER A 77 TYR A 78 GLY A 79 SITE 3 AC6 35 ASP A 80 SER A 82 ASP A 118 ILE A 121 SITE 4 AC6 35 LEU A 132 PHE A 193 ASP A 218 GLY A 220 SITE 5 AC6 35 THR A 221 THR A 222 PHE A 279 GLY A 280 SITE 6 AC6 35 PRO A 281 ILE A 282 HOH A2170 HOH B2002 SITE 7 AC6 35 HOH B2003 HOH B2004 HOH B2005 HOH B2006 SITE 8 AC6 35 HOH B2008 HOH B2009 HOH B2010 HOH B2011 SITE 9 AC6 35 HOH B2012 HOH B2013 HOH B2014 CRYST1 42.580 74.510 42.350 90.00 97.56 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.023485 0.000000 0.003117 0.00000 SCALE2 0.000000 0.013421 0.000000 0.00000 SCALE3 0.000000 0.000000 0.023820 0.00000